World's Best Scientists 2026 revealed!
Hideki Enokida

Hideki Enokida

D-Index & Metrics

Medicine

D-Index
83
Citations
17425
World Ranking
15827
National Ranking
493

Hideki Enokida publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hideki Enokida sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 346 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hideki Enokida D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hideki Enokida sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hideki Enokida is affiliated with Kagoshima University in Japan and has an extensive research record in medicine and related biomedical sciences. Their work primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on oncology and molecular biology applied to urological cancers.

Enokida's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Their subfields of study cover areas such as pulmonary and respiratory medicine, surgery, molecular biology, oncology, and cancer research, reflecting a multidisciplinary approach to medical science.

  • Pulmonary and Respiratory Medicine
  • Surgery
  • Molecular Biology
  • Oncology
  • Cancer Research

The core topics frequently explored in their research involve prostate cancer treatment and diagnosis, bladder and urothelial cancer treatments, epigenetics and DNA methylation, renal cell carcinoma treatment, and radiopharmaceutical chemistry related to oncology.

  • Prostate Cancer Treatment and Research
  • Bladder and Urothelial Cancer Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Epigenetics and DNA Methylation
  • Renal cell carcinoma treatment
  • Radiopharmaceutical Chemistry and Applications
  • Urinary and Genital Oncology Studies

Among the recent publications associated with Hideki Enokida are:

  • "EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer," 2021, published in BMC Cancer
  • "Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma," 2020, published in Cancer Science
  • "Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients," 2020, published in Cancer Science
  • "Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant," 2020, published in PLoS ONE
  • "Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma," 2020, published in PLoS ONE

Their frequent co-authors include Shuichi Tatarano, Hirofumi Yoshino, Takashi Sakaguchi, Yasutoshi Yamada, and Masayuki Nakagawa, indicating collaboration within a network of researchers focused on related biomedical topics.

  • Shuichi Tatarano
  • Hirofumi Yoshino
  • Takashi Sakaguchi
  • Yasutoshi Yamada
  • Masayuki Nakagawa

Hideki Enokida's work has been published predominantly in journals specializing in urology and oncology, including The Journal of Urology, International Journal of Urology, Cancer Science, PLoS ONE, and Journal of Clinical Oncology.

  • The Journal of Urology
  • International Journal of Urology
  • Cancer Science
  • PLoS ONE
  • Journal of Clinical Oncology

Best Publications

  • Small dsRNAs induce transcriptional activation in human cells

    Long-Cheng Li;Steven T. Okino;Hong Zhao;Deepa Pookot

  • miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

    Masayuki Kano;Naohiko Seki;Naoko Kikkawa;Lisa Fujimura

  • Identification of novel microRNA targets based on microRNA signatures in bladder cancer.

    Takahiro Ichimi;Hideki Enokida;Yasushi Okuno;Ryo Kunimoto

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer

    T Chiyomaru;H Enokida;S Tatarano;K Kawahara

  • The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer

    H Yoshino;T Chiyomaru;H Enokida;K Kawakami

  • microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers

    Nijiro Nohata;Toyoyuki Hanazawa;Hideki Enokida;Naohiko Seki

  • MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology

    Yasutoshi Yamada;Hideki Enokida;Satoko Kojima;Kazumori Kawakami

  • Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR

    Takeshi Chiyomaru;Soichiro Yamamura;Shinichiro Fukuhara;Hirofumi Yoshino

  • Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling Pathway

    Shinji Urakami;Hiroaki Shiina;Hideki Enokida;Toshifumi Kawakami

  • Aberrant expression of microRNAs in bladder cancer

    Hirofumi Yoshino;Naohiko Seki;Toshihiko Itesako;Takeshi Chiyomaru

  • Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.

    Takashi Tokizane;Hiroaki Shiina;Mikio Igawa;Hideki Enokida

  • Combination Analysis of Hypermethylated Wnt-Antagonist Family Genes as a Novel Epigenetic Biomarker Panel for Bladder Cancer Detection

    Shinji Urakami;Hiroaki Shiina;Hideki Enokida;Toshifumi Kawakami

  • Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase ( PNP ) in prostate cancer

    S Kojima;T Chiyomaru;K Kawakami;H Yoshino

  • Long Non-coding RNA HOTAIR Is Targeted and Regulated by miR-141 in Human Cancer Cells

    Takeshi Chiyomaru;Shinichiro Fukuhara;Sharanjot Saini;Shahana Majid

  • Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma

    Hideo Hidaka;Naohiko Seki;Hirofumi Yoshino;Takeshi Yamasaki

  • miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.

    Nijiro Nohata;Yaeko Sone;Toyoyuki Hanazawa;Miki Fuse

  • Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer

    Takeshi Chiyomaru;Soichiro Yamamura;Shinichiro Fukuhara;Hideo Hidaka

  • Increased Heparanase Expression Is Caused by Promoter Hypomethylation and Up-Regulation of Transcriptional Factor Early Growth Response-1 in Human Prostate Cancer

    Tatsuya Ogishima;Hiroaki Shiina;Julia E. Breault;Laura Tabatabai

  • Wnt Antagonist Family Genes as Biomarkers for Diagnosis, Staging, and Prognosis of Renal Cell Carcinoma Using Tumor and Serum DNA

    Shinji Urakami;Hiroaki Shiina;Hideki Enokida;Hiroshi Hirata

Frequent Co-Authors

Masayuki Nakagawa
Masayuki Nakagawa Kagoshima University
Naohiko Seki
Naohiko Seki Chiba University
Rajvir Dahiya
Rajvir Dahiya University of California, San Francisco
Peter R. Carroll
Peter R. Carroll University of California, San Francisco
Christopher J. Kane
Christopher J. Kane University of California, San Diego
Yoshitaka Okamoto
Yoshitaka Okamoto Chiba University
Badrinath R. Konety
Badrinath R. Konety University of Minnesota
Seiji Naito
Seiji Naito Kyushu University
Hiromasa Inoue
Hiromasa Inoue Kagoshima University
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering alternative paths to a medical career or want to complement your studies in Medicine, there are several flexible online options. For those interested in advanced nursing roles, online MSN programs for non nurses allow individuals without a nursing background to efficiently enter the field and progress toward higher-paying positions.

Entry into nursing can be competitive, but choosing the easiest RN program to get into can help you kickstart your healthcare career more quickly without lengthy prerequisites or waitlists.

Not every student is aiming for a clinical role. Those interested in the administrative side of healthcare might explore online medical billing and coding schools that accept FAFSA, which can be a quicker and cost-effective pathway to join the industry.

Additionally, some online nursing schools that don't require teas or hesi exams can simplify the application process for aspiring nurses who want to avoid extra standardized tests.

Best Scientists Citing Hideki Enokida

Trending Scientists

Recently Published Articles